Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
716 studies found for:    Open Studies | "Stem Cell Transplantation"
Show Display Options
Rank Status Study
21 Recruiting Autologous Stem Cell Transplantation for Crohn's Disease
Condition: Crohn's Disease
Intervention: Biological: autologous CD34-selected peripheral blood stem cells transplant
22 Recruiting Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
Conditions: Scleroderma;   Cardiac Involvement;   Autologous Stem Cell Transplantation
Intervention: Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
23 Recruiting Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures
Condition: Tibial Fracture
Interventions: Biological: Mesenchymal stem cell injection;   Biological: Placebo
24 Recruiting Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: Donor Bone Marrow stem cell transplantation
25 Recruiting Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
Condition: Recurrent Nasopharynx Carcinoma
Interventions: Drug: Etoposide phosphate;   Drug: Carboplatin;   Drug: Ifosfamide;   Procedure: Autologous Stem Cell Transplantation
26 Recruiting Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
27 Recruiting Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
Condition: Sickle Cell Disease
Interventions: Procedure: Allogeneic Non-Myeloablative Stem Cell Transplantation;   Drug: Alemtuzumab;   Drug: Sirolimus
28 Recruiting Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Other: autologous stem cell transplantation;   Other: conventional chemotherapy
29 Recruiting Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
Conditions: Myeloid Leukemia;   Precursor Myeloid Neoplasms;   Lymphoid Neoplasms
Interventions: Drug: Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
30 Recruiting Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia
Interventions: Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: CXCR4 Antagonist;   Procedure: Hematopoietic Stem Cell Transplantation
31 Recruiting Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Conditions: Triple-Negative Invasive Breast Carcinoma;   Residual Tumor
Interventions: Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation
32 Recruiting Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Condition: Juvenile Myelomonocytic Leukemia
Intervention: Procedure: Stem Cell Transplant
33 Recruiting Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions: Diffuse Large B-cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-cell Lymphoma (DLBCL);   Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Procedure: leukapheresis;   Drug: Plerixafor;   Drug: carmustine, etoposide, cytarabine, melphalan;   Procedure: Autologous Stem Cell Transplantation
34 Recruiting Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
Conditions: Myelodysplastic Syndromes (MDS);   Acute Myelogenous Leukemia (AML)
Intervention: Drug: low dose 5'-azacitidine
35 Recruiting Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation
Condition: Plasma Cell Myeloma
Interventions: Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation--CD34 HSCT;   Procedure: Peripheral Blood Stem Cell Transplantation--AHSCT;   Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation;   Biological: Tetanus Toxoid Vaccine;   Biological: Therapeutic Autologous Lymphocytes;   Biological: Trivalent Influenza Vaccine;   Biological: XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410
36 Recruiting Pilot Trial of Homebound Stem Cell Transplantation
Condition: Plasma Cell Dyscrasia
Interventions: Behavioral: Home monitoring teleconsult visits;   Behavioral: Patient Reported Outcomes (PRO);   Behavioral: Caregiver Reported Outcomes instruments
37 Recruiting Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
Conditions: Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
Interventions: Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
38 Recruiting Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation
Conditions: Stem Cell Transplant During Childhood;   Allogeneic Bone Marrow Transplant During Childhood
Interventions: Other: Questionnaire;   Other: Neurocognitive Evaluation
39 Recruiting SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: SGI-110;   Procedure: Donor Lymphocyte Infusion
40 Recruiting A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Condition: T Cell Non-Hodgkin Lymphoma
Intervention: Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.